Drug Profile


Alternative Names: LP 101; TZP-101; Ulimorelin hydrochloride

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tranzyme
  • Developer Lyric Pharmaceuticals; Norgine; Tranzyme Pharma
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nutrition disorders
  • Discontinued Cachexia; Digestive system disorders; Gastroparesis; Postoperative ileus

Most Recent Events

  • 01 Jul 2016 Phase-II clinical trials in Nutritional disorders in Netherlands, Spain (IV) after July 2016 (NCT02784392)
  • 01 Jul 2016 Phase-II clinical trials in Nutritional disorders in USA (IV) (NCT02784392)
  • 26 May 2016 Lyric Pharmaceuticals plans the phase II PROMOTE trial for Nutrition disorders in USA, Spain and Netherlands (IV) (NCT02784392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top